Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Data Readout On 20 December

 
• By Andrew McConaghie

Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.

Arcus Biosciences
Arcus and Gilead hope their 'Fc-silent' molecule will have a better safety and efficacy profile than other TIGITs. • Source: Shutterstock

More from Business

More from Scrip